You are viewing the site in preview mode

Skip to main content


  • Poster presentation
  • Open Access

ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9 and
  • 10
Journal for ImmunoTherapy of Cancer20142 (Suppl 3) :P92

  • Published:


  • Cervical Cancer
  • Tumor Response
  • Naproxen
  • Listeria Monocytogenes
  • Promethazine


ADXS11-001 immunotherapy is a live attenuated Listeria monocytogenes (Lm) bioengineered to secrete a tLLO-HPV-16-E7 fusion protein targeting HPV-transformed cells. The Lm vector serves as its own adjuvant and infects APC where it cross presents HPV-E7-tLLO fusion peptide, stimulating MHC class 1 and 2 pathways resulting in HPV-E7 specific T cell immunity. Lm-LLO-E7-015 (Clinical Trials Registry India #CTRI/2010/091/001232), is a randomized Phase II study designed to evaluate the safety and efficacy of ADXS11-001 +/- Cisplatin in patients with recurrent cervical cancer in India.


110 patients were randomized to either 3 doses of ADXS11-001 at 1 × 109 cfu or 4 doses of ADXS11-001 at 1 × 109 cfu with Cisplatin chemotherapy (40 mg/m2, weekly x5). Naproxen and oral Promethazine were given as premedications. Patients received CT scans at baseline and 3, 6, 9, 12 and 18 months. The primary endpoint was overall survival.


Final 12-month survival was 32% (35/109), 18-month survival was 22% (24/109) and 24-month survival was 18% (16/91). The response rate was 11% (5 CRs and 6 PRs/109) with tumor responses observed in both treatment arms; 31 additional patients had stable disease 3 months, for a disease control rate of 38% (42/109). Average duration of response in both treatment groups was 9.5 months. Long term survivors (LTS; ≥18 months) included patients with tumor shrinkage and patients with increased tumor burden as their best tumor response overall; 8% (2/24) of LTS failed at least two prior treatments; and 25% (3/11) of LTS were ECOG performance status 2 at baseline. Activity against different high-risk HPV strains was observed. The addition of Cisplatin to ADXS11-001 did not improve survival or tumor response over ADXS11-001 alone but contributed to toxcity. Baseline ECOG performance status, type of prior therapy, or aggressiveness of disease had no significant effect on survival or tumor response. ADXS11-001 was well tolerated as 62% (68/109) of patients reported no adverse events and 38% (41/109) of patients reported only mild transient adverse events (G1-2) that occurred on the day of infusion. The incidence of SAEs possibly related/ related to ADXS11-001 was 1% G3 (0% G4-5).


ADXS11-001 appears to have significant clinical activity in patients with recurrent cervical cancer. The observed prolonged survival, objective tumor responses, and stabilization of recurrent disease compare favorably with more toxic chemotherapy treatment options and support ADXS11-001 as an active agent in the treatment of cervical cancer.

Authors’ Affiliations

Advaxis. Inc, NJ, USA
Central India Cancer Research Institute, Nagpur, Maharashtra, India
Ruby Hall Clinic, Maharashtra, India
Tata Memorial Hospital, Maharashtra, India
Curie Manavata Cancer Center, Maharashtra, India
MV Hospital and Research Center, Chennai, Tamil Nadu, India
Dr. Kamakshi Memorial Hospital, Chennai, Tamil Nadu, India
Smt. Kashibai Navale Medical College and General Hospital, Pune, Maharashtra, India
Christian Medical College Vellore, Vellore, Tamil Nadu, India
Chittaranjan National Cancer Institute, Kolkata, West Bengal, India


© Petit et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.